We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ...

ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.

In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the other small-cap healthcare stocks. In difficult economic times, healthcare equities are ...

In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple ...

Shares of Arvinas ARVN plummeted 52.7% on Tuesday after the company and partner, Pfizer PFE, announced mixed results from a late-stage breast cancer study of its lead candidate, vepdegestrant.

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for ...

Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

Noah Berkowitz, the Chief Medical Officer of $ARVN, sold 8,658 shares of the company on 03-18-2025 for an estimated $74,372. We received data on the trade from a ...

Truist analyst Joon Lee lowered the firm’s price target on Arvinas (ARVN) to $21 from $65 and keeps a Buy rating on the shares as part of a ...